Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial
- PMID: 35704788
- DOI: 10.1200/JCO.22.00669
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial
Comment in
-
Reply to S. Zeng et al.J Clin Oncol. 2022 Sep 10;40(26):3094-3095. doi: 10.1200/JCO.22.01031. Epub 2022 Jun 15. J Clin Oncol. 2022. PMID: 35704836 No abstract available.
Comment on
-
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7. J Clin Oncol. 2022. PMID: 35254888 Clinical Trial.
Similar articles
-
Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?Eur J Cancer. 2016 Feb;54:69-74. doi: 10.1016/j.ejca.2015.11.017. Epub 2015 Dec 25. Eur J Cancer. 2016. PMID: 26724422
-
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7. J Clin Oncol. 2022. PMID: 35254888 Clinical Trial.
-
Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy.Eur Urol Oncol. 2023 Aug;6(4):431-436. doi: 10.1016/j.euo.2022.06.005. Epub 2022 Jul 2. Eur Urol Oncol. 2023. PMID: 35792045 Free PMC article.
-
[Neoadjuvant chemotherapy for invasive bladder cancer].Gan To Kagaku Ryoho. 2001 Nov;28(12):1838-44. Gan To Kagaku Ryoho. 2001. PMID: 11729476 Review. Japanese.
-
Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice.Urol Clin North Am. 2015 May;42(2):181-7, viii. doi: 10.1016/j.ucl.2015.01.002. Epub 2015 Mar 5. Urol Clin North Am. 2015. PMID: 25882560 Review.
Cited by
-
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8+ T cell infiltration and functional transition.J Immunother Cancer. 2023 Oct;11(10):e007230. doi: 10.1136/jitc-2023-007230. J Immunother Cancer. 2023. PMID: 37802603 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical